Skip to Main Content

Paper Details

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Clin Cancer Res
76
2018
BRCA, Niraparib, Ovarian Cancer, PARP, Patients, Platinum, Recurrent, acute myeloid leukemia, anemia, constipation, decreased appetite, dyspnea, epithelial ovarian, fallopian tube, or primary peritoneal cancer, fatigue, gBRCAm, gBRCAm cohort, germline, headache, hypertension, insomnia, mucositis, myelodysplastic syndrome, nasopharyngitis, nausea, neutropenia, niraparib, ovarian, fallopian tube, or primary peritoneal cancer, patients, platinum, poly(ADP-ribose), poly(ADP-ribose) polymerase, rash, recurrent, thrombocytopenia, vomiting
Author NameAffiliation
Hisani N HorneCenter for Drug Evaluation and Research
Hisani N HorneCenter for Drug Evaluation and Research
Reena PhilipCenter for Drug Evaluation and Research
Reena PhilipCenter for Drug Evaluation and Research
Gideon M BlumenthalCenter for Drug Evaluation and Research
Julia A BeaverCenter for Drug Evaluation and Research
  • 1 - 6

Datasets

Release 1.2